What is better for predilatation in bioresorbable vascular scaffold implantation: a non-compliant or a compliant balloon?

被引:6
|
作者
Ozel, Erdem [1 ]
Tastan, Ahmet [1 ]
Ozturk, Ali [1 ]
Ozcan, Emin Evren [1 ]
Uyar, Samet [1 ]
Senarslan, Omer [1 ]
机构
[1] Sifa Univ, Dept Cardiol, 1800 Sok, TR-35540 Izmir, Turkey
关键词
bioresorbable vascular scaffold; predilatation; non-compliant balloon; compliant balloon; OPTICAL COHERENCE TOMOGRAPHY; PERCUTANEOUS CORONARY INTERVENTION; ABSORB COHORT B; APPROPRIATE DEPLOYMENT; STENT SYSTEM; FOLLOW-UP; TRIAL; MULTICENTER;
D O I
10.5152/AnatolJCardiol.2015.6184
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The bioresorbable vascular scaffold system (BVS) is a fully absorbable vascular treatment system. In this study, we aimed to compare the periprocedural effectiveness and long term results of non-compliant balloon (NCB) and compliant balloon (CB) systems, which are used for predilatation before BVS implantation. Methods: One hundred forty-six BVS-treated lesions from 119 patients were retrospectively analyzed in the study. Patients with acute coronary syndrome, stable angina and silent ischemia were included in the study. Lesions and patients were categorized into the NCB and CB groups according to the type of balloon used for predilatation. NCB was implemented on 72 lesions (59 patients) and CB was implemented on 74 lesions (60 patients). The two groups were compared on terms of procedural features and both in-hospital and 1-year clinical follow-up results. Chi-square and independent sample t test were performed for statistical analysis. Results: There was no significant difference between the two groups in terms of patient characteristics and lesion properties. The number of postdilated lesions was significantly higher in the CB group. Procedure time, fluoroscopy time, and contrast volume were significantly lower in the NCB group. At follow-up, one patient had myocardial infarction in the CB group because of scaffold thrombosis and no mortality was observed. Conclusion: Predilatation with NCB before BVS implantation reduces the need for postdilatation. In addition, use of NCB reduces the procedure time, fluoroscopy time, and contrast volume but had no effect on 1 year clinical follow-up results compared with CB.
引用
收藏
页码:244 / 249
页数:6
相关论文
共 50 条
  • [41] Association between inflammatory biomarkers and neointimal response following elective implantation of the ABSORB bioresorbable vascular scaffold
    Rampat, Rajiv
    Williams, Timothy
    Mayo, Thomas
    Mengozzi, Manuela
    Ghezzi, Pietro
    Hildick-Smith, David
    Cockburn, James
    CORONARY ARTERY DISEASE, 2019, 30 (03) : 183 - 187
  • [42] Restenosis patterns after bioresorbable vascular scaffold implantation: Angiographic substudy of the GHOST-EU registry
    Baquet, Moritz
    Nef, Holger
    Gori, Tomasso
    Latib, Azeem
    Capodanno, Davide
    Di Mario, Carlo
    Sabate, Manel
    Colombo, Antonio
    Tamburino, Corrado
    Mehilli, Julinda
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2018, 92 (02) : 276 - 282
  • [43] Combination of Laser Atherectomy and Super High-pressure Non-compliant Balloon to Treat Stent Under-expansion in Cases of Failed Interventional Options
    Sasi, Viktor
    Szanto, Gyula
    Achim, Alexandru
    Ungi, Imre
    Varga, Albert
    Ruzsa, Zoltan
    INTERVENTIONAL CARDIOLOGY-REVIEWS RESEARCH RESOURCES, 2023, 18
  • [44] Everolimus-eluting bioresorbable vascular scaffold implantation to treat saphenous vein graft disease, single-center initial experience
    Picard, Fabien
    Marquis-Gravel, Guillaume
    Avram, Robert
    Ly, Hung Q.
    Dorval, Jean-Francois
    Doucet, Serge
    de Hemptinne, Quentin
    L'allier, Philippe L.
    Tanguay, Jean-Francois
    JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2017, 30 (05) : 433 - 439
  • [45] Optical Coherence Tomography for Coronary Bioresorbable Vascular Scaffold Implantation A Randomized Controlled Trial
    Lee, Seung-Yul
    Kang, Do-Yoon
    Hong, Sung-Jin
    Ahn, Jung-Min
    Ahn, Chul-Min
    Park, Duk-Woo
    Kim, Jung-Sun
    Kim, Byeong-Keuk
    Ko, Young-Guk
    Choi, Donghoon
    Jang, Yangsoo
    Park, Seung-Jung
    Hong, Myeong-Ki
    CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2020, 13 (01) : E008383
  • [46] Implications of a bioresorbable vascular scaffold implantation on vessel wall strain of the treated and the adjacent segments
    Christos V. Bourantas
    Hector M. Garcia-Garcia
    Carlos A. M. Campos
    Yao-Jun Zhang
    Takashi Muramatsu
    Marie-Angèle Morel
    Shimpei Nakatani
    Xingyu Gao
    Yun-Kyeong Cho
    Yuki Isibashi
    Frank J. H. Gijsen
    Yoshinobu Onuma
    Patrick W. Serruys
    The International Journal of Cardiovascular Imaging, 2014, 30 : 477 - 484
  • [47] Impact of post-implantation time on bioresorbable vascular scaffold outcomes for type C versus non-type C coronary lesions: A longer-term study
    Hwang, Juey-Jen
    Kao, Hsien-Li
    Lin, Mao-Shin
    Wu, Cho-Kai
    Chiang, Fu-Tien
    Wang, Yi-Chih
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2023, 122 (10) : 1018 - 1027
  • [48] Rotational Atherectomy Combined With Bioresorbable Vascular Scaffold Implantation: A Feasible Approach for Recurrent In-stent Restenosis When Other Therapies Failed
    Pereira-da-Silva, Tiago
    Patricio, Lino
    Ferreira, Rui Cruz
    JOURNAL OF INVASIVE CARDIOLOGY, 2015, 27 (07) : E143 - E145
  • [49] Bioresorbable vascular scaffold implantation for treatment of recurrent in-stent restenosis: Insights from optical coherence tomography
    Camuglia, Anthony C.
    Lavi, Shahar
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 172 (01) : 238 - 239
  • [50] Early results following everolimus-eluting bioresorbable vascular scaffold implantation for the treatment of in-stent restenosis
    Ielasi, Alfonso
    Latib, Azeem
    Naganuma, Toru
    Cortese, Bernardo
    Sato, Katsumasa
    Miyazaki, Tadashi
    Panoulas, Vasileios F.
    Tespili, Maurizio
    Colombo, Antonio
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 173 (03) : 513 - 514